PainPhase 4NCT00380627
Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)
A Phase 4 study testing MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days in people with Pain, run by Organon and Co.
Trial summary
Allow gynecologists to gain experience with arcoxia for treatment of dysmenorrhea. Read more about this study
- Who is it for?
- Ages 18 to 25 years, women only
- Conditions the study is for
- Pain
- What is being tested?
- MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
- How many people
- 337 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2005to 31 Jan 2006
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Healthy women older than 18 years old and younger than 25 years old
- Voluntary agreement to participate in the study and signature of informed consent
- Women with clinical diagnosis of dysmenorrhea
Who cannot join
- Diagnosis of secondary dysmenorrhea due to: endometriosis, adenomyosis, malformations of Muller's conducts, uterine fibromyomas, ovarian cystic, pelvic varicocoele, inflammatory pelvic disease, adherences, intrauterine devices, cervical channel stenosis, etc.
- Patients with diagnosis of acute inflammatory abdomen
- Patients with diagnosis of congestive heart disease, stroke (1 year), unstable angina, and history of myocardial infarction
- Women auto prescribing rescue medication for dysmenorrheal pain during the study
- Women with a diagnosis of mild dysmenorrhea
About this study
Official title: Quality of Life With Arcoxia in Women With Dysmenorrhea
Allow gynecologists to gain experience with arcoxia for treatment of dysmenorrhea.
- Conditions
- Pain
- Being tested
- MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 DaysDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Perception of menstrual pain, through the analog verbal scale during three days.
Secondary outcomes (1)
Quality of life measures during three days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2006 (estimated)
- Study start1 Sep 2005
- Primary completion31 Jan 2006
- Study completion31 Jan 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 337 participants
Sponsor and investigators
- Lead sponsor
- Organon and Co
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Monitor, Study director, Merck Sharp & Dohme LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00380627
- Sponsor's protocol ID
- 0663-094
- Other IDs
- 2006_035
- Status last verified
- Feb 2022
- First submitted
- 22 Sep 2006
- Last updated
- 15 Aug 2024
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quality of Life With Arcoxia in Women With Dysmenorrhea
- ClinicalTrials.gov ID
- NCT00380627
- Acronym / sponsor ID
- 0663-094
- Conditions
- Pain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 337 participants
- Lead sponsor
- Organon and CoIndustry (pharma, biotech, devices)
- Study start
- 1 Sep 2005 (actual)
- Primary completion
- 31 Jan 2006 (actual)
- Study completion
- 31 Jan 2006 (actual)
- First posted
- 26 Sep 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Allow gynecologists to gain experience with arcoxia for treatment of dysmenorrhea.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 to 25 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Healthy women older than 18 years old and younger than 25 years old
- Voluntary agreement to participate in the study and signature of informed consent
- Women with clinical diagnosis of dysmenorrhea
Key exclusion criteria (5 listed)
- Diagnosis of secondary dysmenorrhea due to: endometriosis, adenomyosis, malformations of Muller's conducts, uterine fibromyomas, ovarian cystic, pelvic varicocoele, inflammatory pelvic disease, adherences, intrauterine devices, cervical channel stenosis, etc.
- Patients with diagnosis of acute inflammatory abdomen
- Patients with diagnosis of congestive heart disease, stroke (1 year), unstable angina, and history of myocardial infarction
- Women auto prescribing rescue medication for dysmenorrheal pain during the study
- Women with a diagnosis of mild dysmenorrhea
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days | Drug | – |
Primary outcome
Perception of menstrual pain, through the analog verbal scale during three days.
1 secondary outcome
Quality of life measures during three days.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2024.
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Monitor study director
Merck Sharp & Dohme LLC
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days in people with Pain, run by Organon and Co.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Perception of menstrual pain, through the analog verbal scale during three days.. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2024.